This seems super relevant for TCR mimetic antibodies and pMHC minibinders…

Same here - maybe they are holding out hope for the shutdown to end so they can keep the panel on schedule. It doesn’t seem likely they could pull it off with this short notice, though.

Good luck - ridiculous situation!

This makes me feel old/nostalgic/proud all at the same time. What a great crew!

I should clarify. We’ve made minibinders to 5-6 different targets now. We don’t get 100% success rate for every binder, but we’ve gotten at least one hit out of 10-20 candidates screened (in line with the rates they indicate in the paper).

I would guess it’s borne out of insecurity - they may not want the burden/responsibility for making final decisions. I think the same issue is pervasive in journal editors when reviewers are conflicted.

Did they really not list the cap in the article!?